Dihexa
Synaptogenic Peptide | Cognitive Enhancement & Neuroprotection
On this page
What is Dihexa?
Dihexa is a small lab-made peptide-like compound, originally developed from angiotensin IV research, that scientists study for its unusually strong effect on synaptogenesis — the formation of new connections between brain cells. Animal research reports it is far more potent than the natural growth factor BDNF at this specific process, primarily in models of memory and cognitive-decline research. It's sold here strictly as a research chemical for laboratory study, not for use in people or animals.
Key terms:
Dihexa is a synthetic oligopeptide.
Dihexa is a short lab-made peptide developed from angiotensin IV. Research reports it strongly supports cognitive function by driving synaptogenesis — the building of new connections between brain cells. Washington State University first developed it for Alzheimer's research. Reports describe it as 7 orders of magnitude (10 million times) more potent than BDNF at forming new synapses. Unusually, it also crosses the blood-brain barrier.
Key research areas
- Dramatic synaptogenesis promotion
- Cognitive enhancement and memory improvement
- Neuroprotection
- Potential neuroregeneration
- May help with Alzheimer's, TBI, and age-related cognitive decline
Researched dosing
This table shows how researchers have structured study dosing schedules for Dihexa across oral and injectable routes in animal research — published research methodology, not personal usage instructions.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Injectable research protocol | 0.5mg/kg | 1x daily | IP/SubQ |
| Cognitive-performance studies | 8-10mg | 1x daily (morning) | Oral |
| Learning-task studies | 10-15mg | 1x daily | Oral |
| Neuroprotection models | 5-8mg | Daily or 3x weekly | Oral or SubQ |
| Maintenance | 5mg | Every other day | Oral |
Commonly cycled 8 weeks on, 2+ weeks off.
How it works
At the cell level, Dihexa research looks at how the compound binds a growth-factor receptor (c-Met) with high affinity, triggering the same synapse-building signaling pathway that BDNF uses, but the animal literature reports it does so at far lower concentrations.
Dihexa binds to hepatocyte growth factor (HGF) with high affinity and potentiates its activity at c-Met receptor, activating PI3K/AKT pathways. This promotes formation of new synaptic connections at levels 10 million times more potent than BDNF. Crosses blood-brain barrier effectively via oral or injectable routes.
Molecular data
These figures — molecular weight and structure — are the chemistry fingerprint researchers use to confirm a Dihexa sample's identity; it's a modified short peptide chain rather than a large protein.
- Weight
- 504.7 Da
- Length
- 0 amino acids
- Type
- Oligopeptide
Hexanoyl-Tyr-Ile-Ahx-NH2 (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide)
Pharmacokinetics
This chart shows how a research dose of Dihexa is absorbed and cleared over roughly two and a half days in animal studies — context for how study designs space out repeat dosing.
- Peak
- 2 hr
- Half-life
- 12 hrs
- Cleared
- ~60 hrs
Harding et al. 2014
Research applications
This section lists the body systems and research areas scientists have studied for Dihexa — largely animal-model memory and neuroprotection research — a summary of what's been investigated in the literature, not medical claims about people.
Cognitive
Significant improvements in spatial memory, working memory, and memory consolidation demonstrated across multiple animal models. Enhanced acquisition of new information and skills through increased synaptic plasticity and neurogenesis. Restoration of cognitive function in models of impairment, including scopolamine-induced amnesia and age-related decline.
Neuroprotection
Protects neurons and supports neuroprotective pathways via PI3K/AKT signaling through HGF/c-Met receptor activation.
Neuroplasticity
Promotes neuroplasticity through sustained synaptogenesis and increased synaptic connections.
Dosage reference
- Doses used in research
- 8–10 mg oral; injectable studies used 0.5 mg/kg.
- Frequency in studies
- 1x daily (morning)
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- 1-3 weeks initial, 4-8 weeks full
- Storage
- Oral capsules: room temperature. Injectable: requires DMSO to dissolve (Dihexa won't dissolve in water), store DMSO stock solution at 2-8°C. Always use pharmaceutical-grade DMSO.
- Cycle length
- 4-8 weeks on
- Break between cycles
- 2-4 weeks off
Interactions
This list shows which other cognitive-research peptides scientists study alongside Dihexa, and flags pairings that call for extra caution in a research setting.
Reconstitution & storage
Dihexa doesn't dissolve in water, so this section describes the specific multi-solvent laboratory method researchers use to prepare an injectable research solution, alongside the simpler oral-capsule form.
- Dihexa does not dissolve in water or ethanol — you must use DMSO as the solvent.
- For a 10mg vial: add 100 µL (0.1 mL) of pharmaceutical-grade DMSO to dissolve the powder completely.
- Add 400 µL (0.4 mL) PEG300 and gently swirl until the solution is clear.
- Add 50 µL (0.05 mL) Tween 80 and gently swirl until clear.
- Add 450 µL (0.45 mL) sterile saline and gently swirl until clear — this gives you 1 mL total at 10 mg/mL.
- The final ratio is 10% DMSO / 40% PEG300 / 5% Tween 80 / 45% saline — always add solvents in this order and make sure the solution is clear before adding the next one.
- For oral: No reconstitution needed — use capsules as provided.
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: Room temperature, use within As per manufacturer specification
Reconstituted: 2-6°C, use within 30 days; avoid repeated freeze-thaw cycles
Open the Dihexa reconstitution calculatorQuality indicators
These are the documentation and sourcing checks researchers use to confirm a Dihexa sample is genuine and properly tested before it goes into a study.
Pharmaceutical Grade - Product from licensed compounding pharmacy with certificate of analysis showing >98% purity.
Proper Storage Conditions - Shipped and stored according to specifications — room temperature for oral, 2-8°C for DMSO stock solutions.
Research Chemical Sources - If sourced as research chemical, ensure third-party testing and proper documentation.
No Testing Documentation - Avoid products without analytical testing, purity reports, or from unverified sources.
Suspicious Pricing - Extremely cheap Dihexa likely indicates poor quality or fraudulent product.
What to expect
This timeline summarizes what animal-model research literature reports at each stage of a study — research context for comparing studies, not a personal-results promise.
Subtle cognitive changes, possible headaches.
Improved focus and memory formation.
Peak cognitive benefits, enhanced learning.
Effects may persist for days to weeks.
Safety notes
This section covers handling cautions and regulatory notes for Dihexa in a laboratory setting — including a theoretical risk flagged in the literature around its growth-factor mechanism — research-use-only scope, not medical safety advice for people.
- Avoid if history of cancer (theoretical cancer risk via c-Met activation)
- Not for pregnant or nursing women
- May cause overstimulation or anxiety
- Requires cycling to prevent tolerance
- No long-term human safety data available
- Not FDA approved - research compound only
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
Dihexa restored spatial learning and memory in Morris water maze tests, increased neuronal cells and synaptophysin expression, reduced neuroinflammation, and decreased glial activation in Alzheimer's model mice.
Reported Dihexa to be 10 million times more potent than BDNF at promoting synapse formation through HGF/c-Met receptor activation in this study.
Intraperitoneal injection at 0.5 mg/kg/day completely reversed scopolamine-induced cognitive deficits (p<0.001), with performance indistinguishable from healthy controls. Lower doses (0.15 mg/kg) showed partial benefits. Also tested IV and ICV routes successfully.